Physician profile
Mark Sanders
NPI 1619018918
$5,083.00
in general payments reported to CMS, 2019-2025
27 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $994 · 2022: $1,105 · 2023: $918 · 2024: $927 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,968 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,967.83 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,086.29 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $979.74 | 2021-2025 | |
| Lilly USA, LLC | $370.31 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $350.11 | 2021-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $292.66 | 2021-2025 | Verquvo, Januvia, Belsomra |
| Glaxosmithkline, LLC. | $262.24 | 2021-2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $219.03 | 2022-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $214.24 | 2022-2024 | Azstarys, Azstarys |
| Lundbeck LLC | $164.03 | 2022-2025 | Rexulti |
| Pfizer INC. | $154.89 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $132.48 | 2021-2023 | Gvoke Hypopen |
| Novo Nordisk INC | $121.91 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $113.21 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $80.20 | 2022 | |
| Dexcom, INC. | $80.16 | 2022-2025 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $71.37 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $69.54 | 2022-2024 | Eliquis |
| Mylan Specialty L.P. | $63.43 | 2024 | Yupelri |
| Amarin Pharma, INC. | $49.58 | 2021 | |
| Ironshore Pharmaceuticals INC. | $46.23 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.87 | 2021-2024 | Jardiance |
| Collegium Pharmaceutical, INC. | $35.53 | 2025 | Jornay Pm |
| Eisai INC. | $25.63 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.22 | 2025 | Caplyta |
| Viatris Specialty LLC | $14.94 | 2025 | Yupelri |
| Idorsia Pharmaceuticals US INC | $14.00 | 2023 | Quviviq |
| Gilead Sciences, INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.